Merrimack Pharmaceuticals Inc. to Present Preclinical Data on Bispecific Antibody MM-111 in ErbB2-Positive Gastric Cancers

Published: Jan 23, 2013

CAMBRIDGE, Mass., Jan. 23, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that preclinical data regarding the bispecific antibody MM-111 will be presented at the American Society of Clinical Oncology 2013 Gastrointestinal Cancers Symposium (ASCO GI), January 24-26, 2013 in San Francisco.

Back to news